Halozyme (HALO) Boosted by ENHANZE Launches and Analyst Upgrade [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
Halozyme Therapeutics, Inc. (NASDAQ:HALO) price target from $79 to $90 while maintaining a Buy rating on the company's shares. The firm stated that Halozyme Therapeutics, Inc. (NASDAQ:HALO) is expected to enhance its multi-year outlook after strong beats and gains in recent quarters. TD Cowen believes that the general forecasts regarding several ongoing ENHANZE launches are “overly conservative,” and that extra resources in late-stage development will likely add momentum to the company's subcutaneous medication delivery technology. Furthermore, Halozyme Therapeutics, Inc. (NASDAQ:HALO) has signed a global collaboration and exclusive licensing deal with Takeda for its ENHANZE drug delivery technology. The agreement states that Takeda will provide an upfront payment to Halozyme Therapeutics, Inc. (NASDAQ:HALO), as well as potential future development and commercial milestone payments. Halozyme Therapeutics, Inc. (NASDAQ:HALO) will also be owed royalties ranging from low to mid singl
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business UpdatePR Newswire
- Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks [Yahoo! Finance]Yahoo! Finance
- How Halozyme's ENHANZE–Vedolizumab Deal With Takeda At Halozyme Therapeutics (HALO) Has Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
- Is Halozyme Therapeutics (HALO) Pricing Reflect Its DCF And P/E Signals After Recent Gains [Yahoo! Finance]Yahoo! Finance
- HALO or AXSM: Which Is the Better Value Stock Right Now? [Yahoo! Finance]Yahoo! Finance
HALO
Earnings
- 11/3/25 - Beat
HALO
Sec Filings
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- HALO's page on the SEC website